Fujirebio Announces Strategic Collaboration with Stanford Medicine
Fujirebio, a leading innovator in in-vitro diagnostics, announced a collaboration with Stanford Medicine to advance research and innovation in the field of infectious disease testing. This collaboration aims to accelerate the adoption of ultrasensitive immunoassays that incorporate single-molecule counting technology developed by Fujirebio’s Silicon Valley wholly-owned subsidiary, Fluxus, Inc. Greater test sensitivity can better inform treatment decisions in the clinic, as well as accelerate studies towards therapeutics and preventive strategies against infectious disease threats worldwide. “Infectious diseases remain one of the greatest global health challenges of our time,” says Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “By working with the Stanford Clinical Virology Laboratory under the direction of Professor Benjamin Pinsky and the Stanford Clinical Microbiology Laboratory under the direction of Professor Niaz Banaei, we are bringing together world-class…
